Fig. 2
From: Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells
Drug screening analyses by target and molecular pathway reveal the synergistic interaction between MS023 and PARP inhibitors. a Synergy Index distribution of the drugs classified by target pathways. Table indicates the enrichment score of each family after the combination screen. Pie chart shows the repartition of each family in the library. Violin plots are classified by target pathways and ordered by enrichment score. Compounds associated with “JAK/STAT” and “DNA Damage” pathways respectively present an enrichment score of 1.10 and 1.68, respectively, suggesting a synergistic interaction with MS023. b Synergy Index distribution of the drugs classified by Molecular targets. Table indicates the enrichment score of each target family within the screen. Pie chart shows the repartition of each family in the library. Violin plots are classified by Molecular targets and ordered by enrichment score. Compounds inhibiting “PARP” and “DNA/RNA Synthesis” present an enrichment of 1.32 and 1.85 respectively, and seems more prone to synergise with MS023. c Synergy indexes of each compound are plotted in function of their cell viability in monotherapy. PARP inhibitors are indicated in the graph